Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol

INTRODUCTION: Hypercalcaemia of malignancy (HCM) is the second most common cause of hypercalcaemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids and calcimimetics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassatne, Aya, Rahme, Maya, Piggott, Thomas, Murad, M. Hassan, Hneiny, Layal, El-Hajj Fuleihan, Ghada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506874/
https://www.ncbi.nlm.nih.gov/pubmed/34635523
http://dx.doi.org/10.1136/bmjopen-2021-051141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506874/
https://www.ncbi.nlm.nih.gov/pubmed/34635523
http://dx.doi.org/10.1136/bmjopen-2021-051141

Ejemplares similares